1 / 6

Diabetic Retinopathy Market share to reach USD 11.1 billion by 2023

Get more information @ http://bit.ly/2kq4uSV <br>Some of the key players in the diabetic retinopathy market include Bayer, Valeant Pharmaceutical, Novartis, F. Hoffmann-La Roche, Alimera Science, Abbott Laboratories, Pfizer, Regeneron Pharmaceutical, and Ampio Pharmaceuticals. Other notable players include Actavis, Boehringer Ingelheim, Kowa group, BCN peptides, ThromboGenics, Bausch & Lomb, iCo Therapeutics, Quark Pharmaceuticals and Vitreoretinal Technologies among others.

jueekate
Download Presentation

Diabetic Retinopathy Market share to reach USD 11.1 billion by 2023

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diabetic Retinopathy Market forecast to reach USD 11.1 billion by 2023: Fractovia.org Fuel Cell Market size worth $25.5bn by 2024

  2. Key Insights of Diabetic Retinopathy Market: • Growing old age population, increasing occurrence of diabetes, fast rise in cases of blindness and rising consciousness about early identification of diabetic retinopathy are the few factors driving the industry expansion. • Diabetic retinopathy is an eye disorder that causes damage to the retina blood vessels. It is a common diabetic condition affecting eyes. Persons suffering from diabetes are at greater risk of developing diabetic retinopathy. • The condition is mainly caused by high levels of glucose in blood producing changes in eye blood vessels. Retinopathy treatment depends upon ailment phase and is aimed at blocking its growth. Corticosteroids injections, vitrectomy and laser surgery are few of the available ailment treatments. • Screening of retina and line of treatment depends upon the seriousness of the situation ensuring delivery of proper treatment. Diabetes is considered to be main cause of blindness in people.

  3. Continued… • To avoid blindness, people are demanding methods for early identification of ailment, fuelling diabetic retinopathy market trends. Also, old age population is more prone for contracting the ailment and hence promotes the industry growth. • Further, technological breakthroughs in retinal screening methods and equipments like utilization of slit lamps and launching of new products like Gly-230 & Optima are the factors predicted to drive the industry expansion. Growing occurrence of diabetes predicted to affect more than 4.6% of world population will also enhance the industry growth. • Different types of diabetic retinopathy are non-proliferative and proliferative. Non-proliferative retinopathy led the industry by contributing more than $4.6 billion in 2015. Growing diabetes occurrence, non-compliant retinal screening of patients and lack of right time diagnosis are factors predicted to fuel the increase in the industry share of non-proliferative retinopathy.

  4. U.S. Diabetic Retinopathy Market size, by management, 2012 - 2023 (USD Million)

  5. Browse Full Market Research Report Diabetic Retinopathy Market @ http://bit.ly/2j826wi Request for a Sample of this Research report @ https://www.fractovia.org/request-sample/136

  6. Stay In Touch Website: https://www.fractovia.org Social Media:

More Related